DV Trading LLC Makes New Investment in SAB Biotherapeutics, Inc. $SABS

DV Trading LLC purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 1st quarter, Holdings Channel.com reports. The firm purchased 400,000 shares of the company’s stock, valued at approximately $1,532,000.

Other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. acquired a new position in shares of SAB Biotherapeutics during the first quarter worth about $29,000. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $32,000. State of Wyoming acquired a new stake in SAB Biotherapeutics in the 4th quarter valued at approximately $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. 7.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wall Street Zen downgraded SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a report on Monday, June 15th. Chardan Capital boosted their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price for the company. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $3.57 on Friday. SAB Biotherapeutics, Inc. has a 52-week low of $1.85 and a 52-week high of $5.15. The company has a market cap of $272.96 million, a P/E ratio of -1.69 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock’s 50-day simple moving average is $3.67 and its 200 day simple moving average is $3.83.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.